

Amendment to the Claims

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1. ~~(currently amended) A Method for the early diagnosis and confirming a diagnosis, for the prognosis and the assessment of the severity and for the therapy-accompanying assessment of the course of sepsis and sepsis-like systemic infections and for the estimation of the risk of a sepsis-risk patient through the formation of a sepsis, characterized in that said method comprising determining the presence and/or amount of anti-asialo-G_{M1} antibodies (anti-AG_{M1} antibodies) and antibodies cross-reacting therewith in a biological fluid blood of a patient in whom sepsis-associated symptoms are present or sepsis risk patient are determined and conclusions are drawn from the presence and/or amount thereof with regard to the presence, the expected course, the severity or the success of a therapy of the inflammatory disease or sepsis or with regard to the risk of a sepsis-risk patient wherein an elevated concentration of anti-asialo-G_{M1} antibodies in said blood compared to a healthy individual is indicative of sepsis.~~
2. ~~(currently amended) The Method according to Claim 1, characterized in that wherein said anti-AG_{M1} and/or anti-G_{M1} (auto)antibodies of the IgG and/or IgA type are determined.~~
3. ~~(cancelled)~~
4. ~~(currently amended) The Method according to Claim 1, characterized in that wherein said determining step the determination is carried out with the aid of a ligand binding assay of the an assay type selected from a sandwich assay, type or of the a competitive assay type or of and an agglutination assay.~~
5. ~~(cancelled)~~

6. *(currently amended)* ~~The Method according to Claim 1, characterized in that it~~wherein ~~is carried out as part of a multiparameter determination, in which at least one further inflammation or infection-sepsis parameter is simultaneously determined and in which a measured result in the form of a set of at least two measured parameters is obtained, which result is evaluated for the fine diagnosis of sepsis.~~

7. *(currently amended)* ~~The Method according to Claim 6, characterized in that, in addition to the anti-gaglioside autoantibodies, wherein at least one further parameter which is selected from the group consisting of the proteins procalcitonin, CA-125, CA-19-9, S100B, S100A proteins, LASP-1, soluble cytokeratin fragments, in particular CYFRA 21, TPS and/or soluble cytokeratin-1 fragments (sCY1F), the peptides inflammin and CHP, peptide prohormones, glycine N-acyltransferase (GNAT), carbamoylphosphate synthetase 1 (CPS-1) and the C-reactive protein (CRP) or fragments thereof is determined as part of the multiparameter determination.~~

8-13. *(cancelled)*